UCB reported EUR1.29B in Selling and Administration Expenses for its fiscal semester ending in December of 2024.


Selling And Administration Expenses Change Date
Alcon AG USD 870M 57M Jun/2025
Almirall EUR 91.3M 55.52M Mar/2025
Amarin USD 36.57M 397K Mar/2025
argenx SE USD 321.35M 45.11M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Bayer EUR 3.55B 162M Jun/2025
Galapagos EUR 30.67M 13.12M Jun/2025
Genmab DKK 144M 18M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
GRIFOLS EUR 282.76M 41.9M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Merck EUR 1.48B 9M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Orion EUR 96.7M 12.4M Jun/2025
Recordati EUR 186.98M 5.59M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
UCB EUR 1.29B 221M Dec/2024
Unibail Rodamco EUR 83.6M 35.6M Dec/2024